Back to top
more

Anika Therapeutics (ANIK)

(Delayed Data from NSDQ)

$25.59 USD

25.59
45,546

+0.77 (3.10%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $25.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ANIK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Anika Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 73 86 94 98 185
Receivables 36 35 30 24 23
Notes Receivable 0 0 0 0 0
Inventories 46 40 36 46 22
Other Current Assets 8 9 8 9 4
Total Current Assets 163 170 169 177 234
Net Property & Equipment 46 48 48 51 51
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1 1 0 0 0
Intangibles 12 82 90 100 15
Deposits & Other Assets 19 17 20 15 7
Total Assets 271 349 348 366 331
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 10 9 8 9 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 21 19 18 15 12
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 4 13 0
Total Current Liabilities 31 28 30 37 16
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 6 10 12 4
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 1 24 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 58 64 60 93 42
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 90 81 67 55 49
Retained Earnings 128 211 226 221 245
Other Equity -6 -6 -6 -5 -6
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 212 286 287 272 288
Total Liabilities & Shareholder's Equity 271 349 348 366 331
Total Common Equity 212 286 287 272 288
Shares Outstanding 14.60 14.60 14.40 14.20 14.20
Book Value Per Share 14.54 19.56 19.94 19.18 20.31

Fiscal Year End for Anika Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 63 69 73 71 65
Receivables 34 32 36 35 37
Notes Receivable 0 0 0 0 0
Inventories 51 49 46 44 43
Other Current Assets 7 9 8 8 8
Total Current Assets 155 159 163 157 152
Net Property & Equipment 48 46 46 46 48
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1 1 1 1 2
Intangibles 11 12 12 76 78
Deposits & Other Assets 20 18 19 19 19
Total Assets 263 264 271 328 329
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 10 10 10 8 8
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 16 18 21 20 16
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 26 28 31 28 23
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 2 3
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 52 55 58 58 55
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 93 91 90 86 82
Retained Earnings 123 124 128 191 198
Other Equity -6 -6 -6 -7 -6
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 210 209 212 270 274
Total Liabilities & Shareholder's Equity 263 264 271 328 329
Total Common Equity 210 209 212 270 274
Shares Outstanding 14.80 14.80 14.60 14.60 14.70
Book Value Per Share 14.21 14.09 14.54 18.53 18.64